{
    "nct_id": "NCT05653882",
    "official_title": "An Open-Label Phase 1a/1b Dose-Escalation and Expansion Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics, and Activity of AB248 Alone or in Combination with Pembrolizumab in Adult Patients with Locally Advanced or Metastatic Solid Tumors",
    "inclusion_criteria": "* Age ≥18 years of age at the time consent is signed.\n* Has adequate end organ function per laboratory testing.\n* Pregnancy prevention requirements\n* Has measurable disease per RECIST 1.1 as assessed by the local site Investigator/radiology.\n* Has a performance status of 0 or 1 on Eastern Cooperative Oncology Group scale.\n* Histologic documentation of incurable, locally advanced or metastatic tumor of the type being evaluated in individual cohorts\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Has a diagnosis of immunodeficiency.\n* Has a history of a previous, additional malignancy, unless potentially curative treatment has been completed, with no evidence of malignancy for 5 years.\n* Has known active CNS metastases and/or carcinomatous meningitis.\n* Has an active autoimmune disease that has required systemic treatment in the past 2 years.\n* Has an active infection requiring systemic therapy.\n* Inability to comply with study and follow-up procedures.\n* Has had a severe hypersensitivity reaction (Grade ≥3) to treatment with pembrolizumab, another monoclonal antibody, or has history of any hypersensitivity to any components of the study treatments or any of their excipients.\n* Has received prior systemic anticancer therapy including investigational agents within 4 weeks (or, if shorter, within 5 half-lives for kinase inhibitors) prior to first dose of study treatment.\n* Has received prior radiotherapy within 2 weeks of start of study treatment or has had a history of radiation pneumonitis.\n* Receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior the first dose of study treatment.\n* Has received previous treatment with another agent targeting the IL-2, IL-7, or IL-15 receptors.\n* Is expected to require any other form of antineoplastic therapy while on study",
    "miscellaneous_criteria": ""
}